Skye Bioscience, Inc. Proceeds from Stock Plans
Skye Bioscience, Inc. (SKYE) reported Proceeds from Stock Plans of $29.57 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockPlans · last filed 2026-03-10
- Skye Bioscience, Inc. proceeds from stock plans for fiscal 2025 was $29.57K.
- Skye Bioscience, Inc. proceeds from stock plans for fiscal 2024 was $0.00.
| Period end | Proceeds from Stock Plans 12 month |
|---|---|
| 2025-12-31 | $29.57K 10-K · filed 2026-03-10 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |